Kurs
+3,32%
Likviditet
93,9 MDKK
Kalender
| Tid* | ||
| 2025-11-14 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-22 | 07:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-09 | 07:30 | Kvartalsrapport 2025-Q1 |
| 2025-04-09 | N/A | Årsstämma |
| 2025-03-05 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-15 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-17 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2024-04-16 | - | Årsstämma |
| 2024-03-06 | - | Bokslutskommuniké 2023 |
| 2023-11-16 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-09 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-31 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2023-03-30 | - | Årsstämma |
| 2023-03-02 | - | Bokslutskommuniké 2022 |
| 2022-11-09 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-09 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-06 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2022-04-05 | - | Årsstämma |
| 2022-03-04 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-21 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2021-04-20 | - | Årsstämma |
| 2021-03-12 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-15 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2020-06-12 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-27 | - | Extra Bolagsstämma 2019 |
| 2019-11-07 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-25 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2019-04-24 | - | Årsstämma |
| 2018-04-18 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2018-04-17 | - | Årsstämma |
| 2017-04-26 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2017-04-25 | - | Årsstämma |
| 2016-04-21 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2016-04-20 | - | Årsstämma |
| 2015-04-24 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2015-04-23 | - | Årsstämma |
| 2014-04-25 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2014-04-24 | - | Årsstämma |
| 2013-04-18 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2013-04-17 | - | Årsstämma |
| 2012-04-17 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2012-04-16 | - | Årsstämma |
| 2011-04-27 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
| 2011-04-26 | - | Årsstämma |
| 2010-04-28 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
COPENHAGEN, Denmark – May 4, 2022 - Bavarian Nordic A/S (OMX: BAVA) will announce its 2022 first quarter results on Monday, May 9, 2022.
The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at https://www.bavarian-nordic.com/investor/events.aspx?event=6388.
To join the Q&A session dial one of the following numbers and state the participant code 7179801: Denmark: +45 32 72 04 17, UK: +44 (0) 844 481 9752, USA: +1 646-741-3167
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company listed on the NASDAQ Copenhagen exchange and with operations in Europe and the USA. Our mission is to save and improve lives by unlocking the power of the immune system and we aspire to become one of the largest pure play vaccine companies by developing innovative life-saving vaccines, excelling in commercialization and being a best-in-class vaccine manufacturer. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next-generation COVID-19 vaccine and a vaccine against respiratory syncytial virus (RSV), which are both entering Phase 3 clinical trials in 2022. For more information visit www.bavarian-nordic.com.
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Tel: +45 61 77 47 43
U.S.: Graham Morrell, Paddock Circle Advisors (US), Tel: +1 781 686 9600